News

According to the terms of the license, Rodan + Fields Dermatologists will develop proprietary formulations for their regimen-based skincare line utilizing the new PiP3 technology with Helix’s patented

The new patent covers Rexahn’s cancer compound, RX-3117, a novel nucleoside chemotherapy agent, which is classified as an antimetabolite. This is said to be the fourth patent in

Sponsored by the National Institute of Allergy and Infectious Diseases, Integral Molecular’s R&D program will utilize its proprietary Lipoparticle technology to discover new ways of inhibiting M2, a

Tricor is a lipid-lowering agent used to treat abnormal lipid levels in the bloodstream, including cholesterol and triglycerides. The product is available in 145mg and 48mg strengths. Bill

Orphan Therapeutics has initiated a rolling NDA with the FDA seeking marketing approval for Lucassin for the treatment of hepatorenal syndromeType 1. Lucassin has been granted the orphan

In an all-cash transaction, WellSpring has purchased the US rights to Micatin (antifungal), Emetrol (anti-nausea), and Gelusil (antacid), and the Canadian rights to Micatin, Gelusil and Glycerin Suppositories

Prior to joining Anesiva, Dr Houghton was chief medical officer of Eleos, a private company. From 2005 to 2007, he was vice president of clinical and regulatory affairs

This agreement is a continuation and expansion of the previous original equipment manufacturer agreement signed between the two companies in April 2005. Under the terms of the agreement,

In his new role, Dr Cohen will oversee development and execution of MAP Pharmaceuticals’s pediatric asthma clinical program, including Phase III clinical trials for unit dose budesonide (UDB).